CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/08/2023
Back to search
Official data from USPTO
PRECISION BIOSCIENCES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PRECISION BIOSCIENCES
ST13
US500000097117501Class
1, 5, 42, 44
Filing
97117501
Registration
7034223
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
05/08/2023
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
11/10/2021
Registration date
04/25/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/25/2023
Last transaction
05/08/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
02/11/2008
First use in commerce
02/11/2008
Drawing code
4
Owner type
03
Owner location
Durham, NC
Examiner
BUSH, KAREN
Law office
L80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Precision BioSciences, Inc.
Representatives
Eva Gullick Frongello Parker Poe Adams & Bernstein LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
genome editing reagents for research purposes; Chemicalbiochemicalbiotechnological products intended for industryagriculturehorticulturepolypeptides for in vivo and in vitro genetic engineeringnatural and engineered meganucleases and endonucleasesnucleic acid vectorsmolecular scissors; chemicalbiochemicalbiotechnological and bacteriological products intended for research laboratories and control laboratoriespolypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologicsengineered proteins for gene regulationgenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgene modificationgene correctionall for use in scientific researchpharmaceutical researchagricultural biotechnologydiagnosticsindustrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseasesgene therapycell therapy; biochemicals and biologicsengineered nucleic acidsviral vectorsnon-viral vectorsgene therapy vectorsgene editing vectorsgenetically modified cellsengineered proteins for multiplexed gene editingmRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cellsantibody preparationsCAR T-cell preparationsT-cell preparationsB-cell preparationsTreg preparationsNK cell preparationsall for use in scientific research and analysis and diagno
Class 5
pharmaceutical preparationscell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cellsgenetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on genegenome and cellular editingmodulationmodificationengineeringregulationrepair and therapy for use in human therapeuticstherapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascularcentral nervous systemendocrinegastrointestinalgenetic immunologicalinfectiousinflammatorymenopausalmetabolicautoimmunemusculoskeletalneurologicalophthalmologicalpsychiatricrespiratoryurogenitalurologicalhematologic and viral diseases and disorders; pharmaceutical preparationstherapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunctionsexual dysfunctioncancerpain and diabetes; pharmaceutical preparationstherapeutic pharmaceuticals developed through genome modificationsantifungal preparationsdermatological preparationssmoking cessation preparations and tissue repair preparations; engineered nucleic acidsviral vectorsnon-viral vectorsgene therapy vectorsgene editing vectorsgenetically modified cellsengineered proteins for multiplexed gene editingmRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cellsantibody preparationsCAR T-cell preparationsT-cell preparationsB-cell preparationsTreg preparationsNK cell preparationsall for clinical usemedical useclinical laboratory usemedical laboratory use
Class 42
research in the fields of genome editinggene editinggenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgenetic diseasegene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in geneticmedicalpharmaceutical and veterinary fields; scientific research in chemistrybiologybiochemistrymolecular biologybacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer
Class 44
Medical servicescellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating diseasethe treatment of cancer
Publications
History of USPTO decisions and trademark events.
26 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/08/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/08/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/08/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/08/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/25/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/25/2023
ATRV
ATTORNEY REVIEW COMPLETED
03/06/2023
LOPR
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
03/06/2023
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
03/06/2023
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
03/01/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
01/18/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/20/2022
PUBO
PUBLISHED FOR OPPOSITION
12/20/2022
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
12/15/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/30/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/17/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/02/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/02/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/02/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/12/2022
GNRT
NON-FINAL ACTION E-MAILED
05/12/2022
CNRT
NON-FINAL ACTION WRITTEN
05/12/2022
DOCK
ASSIGNED TO EXAMINER
05/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/17/2021
NWAP
NEW APPLICATION ENTERED
11/13/2021
Continuous trademark protection
Get notified about every new filing that threatens PRECISION BIOSCIENCES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.